Navigation Links
Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugai's Actemra for Rheumatoid Arthritis
Date:8/6/2008

However, Pharmacy Directors Disagree About Formulary Inclusion for Key Emerging Biologic Agents That Will Launch for the Disease in the Next Few

Years, According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 89 percent of surveyed rheumatologists anticipate prescribing Roche/Chugai's Actemra, following the expected launch of the drug for rheumatoid arthritis in 2009. Surveyed rheumatologists indicated they would prescribe Actemra, an interleukin-6 inhibitor, to an estimated 10 percent of their patients six months after the drug's launch. On July 29, 2008, the Food and Drug Administration's Arthritis Advisory Committee recommended Actemra's approval for rheumatoid arthritis. Although some panel members expressed concern about data that suggested the potential for negative side effects, the committee indicated that clinical trials supported Actemra's efficacy.

The new Physician & Payer Forum report, Biologics in Rheumatoid Arthritis: Physician and Payer Perspective on Recently Launched and Emerging Biologics in Rheumatoid Arthritis, finds that rheumatologists are highly receptive to the many new agents expected to launch by 2011, but they may face increasing barriers to reimbursement and limited access to novel biological agents.

In addition to Actemra, the other emerging biologic agents included in the report survey are UCB's Cimzia, Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's golimumab and Biogen Idec/Genentech/Roche's ocrelizumab. The report finds that managed care organizations' (MCO) pharmacy directors disagree on the likelihood of formulary inclusion for key emerging biologics as their expectations varied widely in response to whether they will include these agents on their formularies. Pharmacy directors may be reserving judgment on key biologic agents un
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Thoratec Reports 44 Percent Increase in Second Quarter Revenues;
2. Mothers from affluent neighborhoods near highways increase odds of low weight babies by 81 percent
3. A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market
4. Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance
5. Galderma announces approval for Differin gel 0.1 percent in Japan
6. 89 percent of childrens food products provide poor nutritional quality
7. Statement on CDC Announcement That 70 Percent of the U. S. Population Now Receives Optimally Fluoridated Water By Mark J. Feldman, DMD, President, American Dental Association
8. Cadaver tissue fails nearly 25 percent of the time in young ACL reconstructions
9. Primary Care Physicians Prescriptions of Aricept for Alzheimers Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008
10. Disaboom Survey Reveals 52 Percent of Americans Would Rather be Dead Than Disabled
11. Economist Finds Highmark/IBC Merger Would Result in 70 Percent Share in Pennsylvania, Far Higher Than Initial Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... (PRWEB) March 28, 2015 Could genetic ... a new study by researchers at the ... Produced with the support of the Coffee and Caffeine ... Molecular Psychiatry this past fall, the study—one of several ... of genomic data from more than 120,000 regular coffee ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians ... osteoarthritis and musculoskeletal diseases gathered here for the ... first time in the 17-year history of the ... topic is an emerging non-pharmaceutical protocol for enhancing ... of Wolff’s law, osteogenic loading at multiples of ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New ... recently commemorated its three-year anniversary of being the only ... to 24-hour urgent care, Emergency Medical Care offers its ... time, Emergency Medical Care’s Urgent Care NYC ... eye injuries, ear infections, fevers, insect bites, burns, animal ...
(Date:3/28/2015)... Centurion Service Group will be hosting a live on-site ... their Las Vegas warehouse, located at 4606 Andrews St. Suite ... of equipment from hospitals and surgery centers from around the ... , Buyers will find items of all types including anesthesia, ... said Erik Tivin, CEO of Centurion. , Among the sale’s ...
(Date:3/28/2015)... How best to treat and recover from ... medicine. While diagnostic hip injections are commonly performed for ... research presented today at the American Orthopaedic Society for ... pain relief from this diagnostic injection may not predict ... study looked to assess if the amount of pain ...
Breaking Medicine News(10 mins):Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2
... prime minister Jose Socrates is smiling. His move to lift a ... voting doing so in favor of the ban being lifted or, ... and Poland- strong catholic nations that prohibit abortion or destruction of ... abort can face up to 3 years prison term and those ...
... monitored more carefully according to reports sounded at the ... a higher risk of giving birth to still-born babies, than ... Yale School of Medicine, who put forward results made after ... ,It was seen that the risk of intrauterine fetal ...
... increases a woman’s risk of becoming infected with HIV, ... edition of The Journal of Infectious Diseases (now online). ... sexually transmitted infections increase the risk of transmission and ... of Trichomonas vaginalis per year worldwide, there are few ...
... alloy surfaces containing at least 90 per cent copper completely ... of the pathogen-killing// properties of the metal. ,The ... on the mix of metals they use to coat the ... better means of eliminating E coli contamination in their products. ...
... The South African AIDS Vaccine Initiative (SAAVI) and the HIV ... of a Phase IIb study utilizing// Merck’s adenovirus trivalent (Ad5 ... and women over a year, and expect the study to ... (HVTN 502) began enrolling in North and South America, the ...
... Researchers at Cold Spring Harbor Laboratory (CSHL) have solved ... critical tumor suppressor gene, but have revealed// a master ... targeted and effective cancer therapy in the future," said ... by Mills, was published in the February issue of ...
Cached Medicine News:Health News:Vaginalis Increases the Risk of Becoming Infected With HIV 2Health News:Vaginalis Increases the Risk of Becoming Infected With HIV 3Health News:Copper Alloys Surfaces Touted As Pathogen Killers 2Health News:Largest Ever African HIV Vaccine Trial Opens in South Africa 2Health News:Scientists Discover New Gene 2
(Date:3/27/2015)... BEIJING , March 27, 2015 ... the "Company") (NYSE: CCM ), a leading ... the largest network of radiotherapy and diagnostic imaging ... announced the signing of a purchase agreement under ... wholly owned subsidiary of the Company, agreed to ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... with a focus on Omega-3 therapies for cardiovascular disease ... it issued 763,752 common shares of the Corporation (the ... for the period of December 5 th , 2014 ... Convertible Notes that is due on or before April ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
Breaking Medicine Technology:Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
... SEATTLE, May 9 The risk of the two ... be,reduced by changes in lifestyle, such as avoiding smoking, ... Kristal, Dr.P.H., associate,head of the Cancer Prevention Program at ... studies that suggest men need not,feel helpless against prostate ...
... - Fifth International Phase III Study Shows Positive Results with X-ray ... ... May 9 Roche today announced one-year,results from a new two-year Phase ... to,joints in patients with rheumatoid arthritis (RA), a critical measure of,effectiveness of ...
Cached Medicine Technology:Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 2Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 3Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5
... Clinical is an open platform for clinical diagnostic ... deck sizes of 75, 100, 150 and ... for your laboratory space and throughput requirements. Tecan ... to allow new applications and to evolve the ...
... maximum productivity, and proven reliability, Sorvall ... fully automatic cell washing and centrifugation ... 80-second wash cycle for stat testing, ... and standardized, reproducible procedures. High reliability, ...
Excellent all-around performance in digital format - MIC-D offers an exciting new way to observe the natural world. Multiple performance features provide new ways to enjoy microscope observation....
... model centrifuge. High throughput, refrigeration maintains ... with all windshield rotors, lifetime reproducibility, ... a remote personal computer or laboratory ... imbalance detection and shut down, armor ...
Medicine Products: